Plain-English translation of NCT05271214 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is for people with severe heart failure who have been referred for a mechanical heart pump device (LVAD). Instead of immediately having surgery, you would receive intensive medications including furosemide, milrinone, beta blockers, hydralazine, nitrates, and digoxin to stabilize your heart. The goal is to see whether careful medical management and repeated heart testing over time might help you improve enough to delay or avoid the surgery altogether.
Heart pump devices are life-saving but come with risks and complications. Doctors want to know if some patients can improve enough on strong medications that they might not need surgery right away, or might avoid it entirely.
You likely qualify if…
You likely don't qualify if…
You would be admitted to the hospital for initial stabilization with intravenous medications. Over the following months, you would have repeated visits with comprehensive heart testing including ultrasound imaging, exercise stress tests, and blood work to see if your heart is improving. Your medications would be carefully adjusted based on how you're responding. The doctors will keep re-evaluating whether you still need the heart pump surgery or if the medical treatment is working well enough that you can avoid it.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Israel
Sponsor
Tel-Aviv Sourasky Medical Center
Enrollment target
~100 participants
Started
January 2018
Primary completion
January 2028
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in March 2022.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ofer Havakuk, MD
Tel-Aviv Sourasky Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.